论文已发表
注册即可获取德孚的最新动态
IF 收录期刊
Authors Petryk N, Shevchenko O
Received 14 April 2020
Accepted for publication 27 June 2020
Published 7 July 2020 Volume 2020:13 Pages 293—301
DOI https://doi.org/10.2147/JIR.S256932
Checked for plagiarism Yes
Review by Single-blind
Peer reviewer comments 2
Editor who approved publication: Dr Ning Quan
Introduction: Many widespread intractable diseases are
caused or supported by chronic inflammation. Such conditions include the 2nd
type of diabetes mellitus, atherosclerosis, neurodegenerative diseases, chronic
inflammatory diseases of the connective tissue - ankylosing spondylitis,
rheumatoid arthritis, autoimmune myositis, etc. Therefore, the search for
targeted treatment of these illnesses is extremely in high demand.
Immunomodulatory activity of mesenchymal stem cells is one of their remarkable
properties. Several biomarkers (cytokines and nonspecific proteins) are known
to be associated with chronic inflammation.
Methods: Our
study aimed to investigate the serum levels of tumor necrosis factor-alpha,
interleukin 6 and C-reactive protein in carrageenan myositis in rats, because
there is more and more evidence of the significance of these markers in the
course and resolution of the diseases mentioned above. For the first time in
our experiment, it was shown and evaluated using analysis of variance, how MSCs
influence the indicators of proinflammatory cytokines on the model of
carrageenan myositis. The levels of α-TNF, IL-6 and CRP in the plasma of rats
were studied in groups with chronic carrageenan inflammation and chronic
inflammation with local injection of MSCs into the affected area.
Results: Our
study proved the effectiveness of MSCs by showing a significant decrease in the
levels of inflammatory mediators in the plasma of the studied animals.
Discussion and Conclusions: Thus, the administration of MSCs is a promising
tool in the pathogenic treatment of chronic inflammation and concomitant
conditions.
Keywords: chronic
inflammation, mesenchymal stem cells, carrageenan, tumor necrosis factor-alpha,
interleukin-6, C-reactive protein